Passage Bio is moving to exit its strategic review after tough FDA feedback, agreeing to a reverse merger with Remix Therapeutics. The all-stock transaction transfers the Nasdaq listing path to Remix, while positioning the small-molecule mRNA degrader effort as the core of the combined entity. The deal highlights how gene and cell-adjacent companies can pivot when regulatory pathways stall—by changing corporate structure rather than waiting through longer standalone development timelines.